Second Study in ACTG’s Small Clinical Trials Advancing HIV Remission and Cure ProgramCHAPEL HILL, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new sequential immunization strategy shows strong promise for an HIV vaccine, a ...

The 2026 State of HIV Stigma Report released by GLAAD shows a growing divide between medical progress and public ...

It's a twice-a-year injection that is remarkably effective in preventing an HIV infection. Distribution is starting. But questions are being raised about getting it to the areas that need it most.

Inbound students made up over half of the 46 HIV cases found among nearly 40,000 tests, researchers say International ...

A cure for HIV would be one of the greatest medical achievements in modern history. But the day a cure is celebrated could ...

For the past four decades, oral antiretroviral therapy for HIV has required daily doses. Long-acting injectable cabotegravir ...

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said. The data sets the stage for likely FDA approval of lenacapavir for HIV prevention. Shares rose 3% in ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. NAKURU, KENYA - 2026/03/26: A healthcare worker fills a syringe with a dose of lenacapavir, ...

A similar model of bringing testing into less engaged communities could potentially be implemented elsewhere with adequate funding, resources, and buy-in.

HIV health providers have already absorbed some cuts and fear more. They worry that gains made toward eliminating the virus are in jeopardy. The post ‘We are living in reverse.’ Fragile HIV funding ...